启动港股IPO！国产减重代谢疾病创新械企

Core Viewpoint - Hangzhou Tangji Medical Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, aiming for a main board listing, with ICBC International and Caitong International as joint sponsors [2]. Industry and Market Size - Tangji Medical operates in the medical health sector related to metabolic diseases, which are among the heaviest burdens on global healthcare systems, including obesity, overweight, type 2 diabetes, and metabolic-associated fatty liver disease (MASH) [5]. - In 2021, approximately 6.7 million deaths globally were attributed to diabetes, with around 1.4 million in China, corresponding to medical expenditures of $966 billion and $165 billion, respectively. The demand for medical services related to metabolic diseases is expected to continue growing due to aging populations, lifestyle changes, and increased disease screening rates [8]. Company Overview - Founded in 2016, Tangji Medical focuses on the research and commercialization of medical devices. The company has established multiple wholly-owned or controlling subsidiaries to drive its industrial layout through collaborative efforts [4][13]. - The organizational structure reflects a typical R&D-driven model, with business operations not centralized under a single entity but rather distributed across various entities to enhance regional and phase-specific business development [13]. Product Introduction - Tangji Medical's product line is centered around medical devices, with a systematic classification based on specific application scenarios. The company has developed multiple product lines that cover different niche applications, with some products already in commercialization or registration stages [18]. - The gastric bypass stent system, a key product, utilizes a minimally invasive approach to reduce sugar and fat absorption, showing an average weight loss of 9 kg over three months and significant improvements in metabolic disease-related blood indicators [20]. Financial and Stage Assessment - Tangji Medical is currently not profitable, primarily due to accumulated tax losses and ongoing R&D expenditures, which are characteristic of early-stage medical device companies [21]. - The company is positioned more as a long-term player focused on chronic disease and metabolic health needs rather than a short-term performance-driven IPO case [22]. Future Outlook - The company's ability to gain further recognition in the capital market will depend on the successful market launch and performance of its core products [23].